Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
PMCID: PMC4215190
Store only in the original container
20 mg = 2 kit 30 mg = 3 kit etc
10.1186/s12935-022-02496-z 178 WenJ.YiZ.ChenY.HuangJ.MaoX.ZhangL.et al (2022)
Phase 3 Outlook: Based on Phase 2 results, a Phase 3 trial is planned for the first half of 2025 to evaluate the co-formulated bremelanotide plus PDE5 inhibitor combination in PDE5i non-responders
Supplementary information This file contains all uncropped blot information and is referenced by each figure legend of the cropped blots This file contains the material and methods section including information about the synthesis of a coumarin-quinone conjugate ((2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate) and C9-Hyponitrite ((E)-1,2-bis((2-methyldecan-2-yl)oxy)diazene) Supplementary Video | FSP1 protects cells from RSL3 induced ferroptosis (download AVI Live cell microscopy showing an overlay of Hoechst (blue
US$ 20.86
US$ 23.32
US$ 21.10
US$ 21.31
US$ 22.25
US$ 23.85
US$ 25.33
US$ 22.27
US$ 21.31
